Market Overview

The global targeted DNA/RNA sequencing market reached USD 13.9 Billion in 2024 and is projected to reach USD 48.1 Billion by 2033, growing at a CAGR of 14.77% during 2025-2033. This growth is propelled by the rising prevalence of chronic and infectious diseases, expanded adoption of NGS technologies, and continuous technological advancements. Targeted sequencing offers higher depth and cost efficiency, enabling precise analysis using PCR and hybrid capture techniques. 

Study Assumption Years

• Base Year: 2024
• Historical Years: 2019-2024
• Forecast Period: 2025-2033

Targeted DNA/RNA Sequencing Market Key Takeaways

• The market size stood at USD 13.9 Billion in 2024, with a CAGR of 14.77% expected through 2025-2033.
• The growth is driven by the increasing burden of chronic and infectious diseases alongside technological progress.
• Rising use of solvent biopsies and cell-free circulating tumor DNA (ctDNA) is fueling cancer diagnostics.
• Genome mapping efforts targeting illnesses like diabetes, cancer, and psychiatric disorders are expanding the market.
• Innovations such as cloud-computing integration in NGS systems are reducing costs and improving data management.
• Increasing demand for non-invasive testing and personalized medicine supports market expansion.

Sample Request Link: https://www.imarcgroup.com/targeted-dna-rna-sequencing-market/requestsample

Market Growth Factors

The rising incidence of chronic and infectious diseases is one of the major factors that is fuelling the growth of the market for targeted DNA/RNA sequencing. The rising incidence of diseases such as diabetes, heart disease, asthma, cancers, and psychiatric disorders has been emphasized to have escalated to an alarming extent. This has increased the demand for accurate genetic evaluation tools like targeted DNA/RNA sequencing, as it allows intensive research on DNA/RNA mutations that cause these diseases. Secondly, these sequencing tools help predict the onset of diseases that occur due to genomic mapping initiated by the scientific community globally.

The use of next-generation sequencing (NGS) techniques is snowballing at a rapid rate as the applications of solvent biopsis are on the rise for diagnosing cancer. The techniques employ non-invasive biological markers, namely cell-free circulating DNA, which makes it possible to diagnose and track cancers in real-time. Such novel technology gives a massive competitive advantage to the techniques used for diagnosing as it improves outcomes for patients and thereby creates greater demand for the market.

Technological innovation remains a positively driving force within the industry. For instance, the incorporation of cloud computing platforms within NGS technology improves the management of information while lowering the associated costs. Moreover, with the current rising interest in personal medicine that offers precise diagnoses and treatment, there is an increased need for targeted DNA/RNA sequencing. The continued R&D within exome sequencing, molecular biology, and technical engineering, as well as collaboration between the public and private sectors, further fuels innovation within the industry.

Market Segmentation

Technology Insights:

• NGS: Next-Generation Sequencing represents the largest technology segment, indicating wide adoption of advanced sequencing methods.
• Others: Additional sequencing technologies also contribute to the market but with smaller shares.

Workflow Insights:

• Presequencing: Preparation steps before sequencing are crucial for accuracy.
• Sequencing: Identified as the largest workflow segment, this step involves the actual processing of DNA/RNA samples.
• Data Analysis: Post-sequencing computational analysis helps interpret results effectively.

Application Insights:

• Human Biomedical Research: Studies involving human genetics.
• Plant and Animal Sciences: Sequencing applied in agricultural and biological research.
• Drug Discovery: The largest application segment, highlighting its role in identifying drug targets and therapies.
• Others: Additional applications in various research areas.

Type Insights:

• DNA-Based Targeted Sequencing: Dominates the market, used for DNA-specific investigations.
• RNA-Based Targeted Sequencing: Focused on RNA-based genetic analysis.

End User Insights:

• Hospitals & Clinics: Healthcare providers utilizing sequencing for diagnostics.
• Academic & Research Institutes: The largest end-user segment, emphasizing research-driven demand.
• Pharma & Biotech Companies: Industry players engaged in drug development and diagnostics.

Regional Insights

North America is the dominant region in the targeted DNA/RNA sequencing market, driven by the rising prevalence of chronic diseases, adoption of NGS technologies, and growing demand for personalized medicine. The report identifies the United States and Canada as key contributors to the regional market leadership.

Key Players

• Agilent Technologies Inc.
• BGI Group
• Dnastar Inc.
• Eurofins Genomics LLC (Eurofins Scientific SE)
• F. Hoffmann-La Roche Ltd
• Illumina Inc.
• Integrated DNA Technologies, Inc. (Danaher Corporation)
• Macrogen Inc
• Oxford Nanopore Technologies plc
• PacBio
• Pieriandx
• QIAGEN N.V.
• Thermo Fisher Scientific Inc.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

Request for customization: https://www.imarcgroup.com/request?type=report&id=12570&flag=E

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No: (D) +91 120 433 0800

United States: +1-201971-6302